Suchergebnisse - "Shi, Yuankai"

PubPharm (48)

1

Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6) : single-arm, open-label, multicentre, phase 2 trial

enthalten in: The Lancet. Respiratory medicine | 2024

von Wang, M. | Fan, Y. | Sun, M. | +37

2

Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer : a phase Ⅱ study

enthalten in: EBioMedicine | 2024

von Yang, L. | Zhang, W. | Fan, N. | +24

3

Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation : A pooled analysis of two clinical studies

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2023

von Yang, S. | Wu, S. | Zhao, Y. | +54

4

Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer : a pooled analysis from two phase 2 studies

enthalten in: BMC medicine | 2023

von Hu, X. | Zhang, S. | Ma, Z. | +27

5

Efficacy and safety of immunotherapy combined with single-agent chemotherapy as second- or later-line therapy for metastatic non-small cell lung cancer

enthalten in: Frontiers in immunology | 2023

von Chen, D. | Li, L. | Wang, M. | +8

6

Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study

enthalten in: BMC medicine | 2023

von Shi, Y. | Zhou, J. | Zhao, Y. | +13

7

Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG) : a multicentre, double-blind, randomised phase 3 study

enthalten in: The Lancet. Respiratory medicine | 2022

von Shi, Y. | Chen, G. | Wang, X. | +20

8

Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC : A Phase 2b Study

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2022

von Shi, Y. | Wu, S. | Wang, K. | +46

9

Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC : Results From the FURLONG Study

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2022

von Shi, Y. | Chen, G. | Wang, X. | +19

10

Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC : A Multicenter, Single-Arm, Phase 2b Study

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2022

von Shi, Y. | Li, B. | Wu, L. | +38

1
2
3
4
5
Nächster »
[5]